---
title: "CMB International Securities Keeps Their Buy Rating on Akeso, Inc. (9926)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305767303.md"
description: "CMB International Securities analyst Jill Wu maintained a Buy rating on Akeso, Inc. today and set a price target of HK$99.34.Wu covers the Healthcare sector, focusing on stocks such as Innovent Biologics, Hansoh Pharmaceutical Group Company Limited, and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H. According to TipRanks, Wu has an average return of 23.5% and a 52.97% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akeso, Inc. with a HK$152.82 average price target."
datetime: "2026-11-17T05:15:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305767303.md)
  - [en](https://longbridge.com/en/news/305767303.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305767303.md)
generator: "portal-rs"
---

# CMB International Securities Keeps Their Buy Rating on Akeso, Inc. (9926)

CMB International Securities analyst Jill Wu maintained a Buy rating on Akeso, Inc. today and set a price target of HK$99.34.

Wu covers the Healthcare sector, focusing on stocks such as Innovent Biologics, Hansoh Pharmaceutical Group Company Limited, and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H. According to TipRanks, Wu has an average return of 23.5% and a 52.97% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akeso, Inc. with a HK$152.82 average price target.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)
- [06990.HK](https://longbridge.com/en/quote/06990.HK.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**